Quanterix

The awards will support clinical validation, manufacturing, and scale up for SARS-CoV-2 viral antigen and molecular detection.

News items for the week of August 10, 2020.

The company said that it has priced a public offering of 2,651,108 shares of its common stock at $32 per share.

The company posted Q2 revenues of $13.1 million, down from $13.5 million in Q2 2019 but above the consensus Wall Street estimate of $11.8 million.

The firm said its test is one-thousandfold  more sensitive than conventional SARS-CoV-2 serology tests and could enable earlier antibody detection in patients.

The company posted Q1 revenues of $15.7 million, up from $12.3 million in Q1 2019 and above the consensus Wall Street estimate of $13.3 million.

Single-cell and single-molecule proteomics tools developed for the immuno-oncology market are proving useful for studying the immune response in COVID-19.

The company posted Q4 revenues of $15.9 million, up from $10.9 million in Q4 2018, and beat the consensus Wall Street estimate of $14.2 million.

Exact Sciences CEO Kevin Conroy discussed the firm's pipeline and plans for 2020 and beyond, while NanoString CEO Brad Gray talked about the company's GeoMx digital spatial profiling technology, among other presentations Wednesday.

The firm reported $14.9 million in revenue, driven by an 80 percent increase in product revenues, beating Wall Street expectations.